Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure
Top Cited Papers
Open Access
- 22 March 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (3), e0174099
- https://doi.org/10.1371/journal.pone.0174099
Abstract
Emerging evidence has suggested a potential impact of gut microbiota on the pathophysiology of heart failure (HF). However, it is still unknown whether HF is associated with dysbiosis in gut microbiota. We investigated the composition of gut microbiota in patients with HF to elucidate whether gut microbial dysbiosis is associated with HF. We performed 16S ribosomal RNA gene sequencing of fecal samples obtained from 12 HF patients and 12 age-matched healthy control (HC) subjects, and analyzed the differences in gut microbiota. We further compared the composition of gut microbiota of 12 HF patients younger than 60 years of age with that of 10 HF patients 60 years of age or older. The composition of gut microbial communities of HF patients was distinct from that of HC subjects in both unweighted and weighted UniFrac analyses. Eubacterium rectale and Dorea longicatena were less abundant in the gut microbiota of HF patients than in that of HC subjects. Compared to younger HF patients, older HF patients had diminished proportions of Bacteroidetes and larger quantities of Proteobacteria. The genus Faecalibacterium was depleted, while Lactobacillus was enriched in the gut microbiota of older HF patients. These results suggest that patients with HF harbor significantly altered gut microbiota, which varies further according to age. New concept of heart-gut axis has a great potential for breakthroughs in the development of novel diagnostic and therapeutic approach for HF.Keywords
Funding Information
- Japan Society for the Promotion of Science (KAKENHI 26670395)
- Takeda Pharmaceutical Co., Ltd.
- Daiichi Sankyo Co., Ltd.
- Shionogi
- Nippon Boehringer Ingelheim Co., Ltd.
- Bristol-Myers Squibb K.K.
- MSD K.K.
- Sanofi K.K.
- Sumitomo Dainippon Pharma Co., Ltd.
- Japan Agency for Medical Research and Development (M1501)
- Japan Agency for Medical Research and Development (M1501)
This publication has 47 references indexed in Scilit:
- Robustness of Gut Microbiota of Healthy Adults in Response to Probiotic Intervention Revealed by High-Throughput PyrosequencingDNA Research, 2013
- The human microbiome: at the interface of health and diseaseNature Reviews Genetics, 2012
- Intestinal microbiota determine severity of myocardial infarction in ratsThe FASEB Journal, 2011
- UniFrac: an effective distance metric for microbial community comparisonThe ISME Journal, 2010
- Composition, variability, and temporal stability of the intestinal microbiota of the elderlyProceedings of the National Academy of Sciences of the United States of America, 2010
- Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestineFEMS Microbiology Letters, 2009
- Quantitative and Qualitative β Diversity Measures Lead to Different Insights into Factors That Structure Microbial CommunitiesApplied and Environmental Microbiology, 2007
- An Improved DNA Isolation Method for Metagenomic Analysis of the Microbial Flora of the Human IntestineMicrobes and Environments, 2007
- Contribution of acetate to butyrate formation by human faecal bacteriaBritish Journal of Nutrition, 2004
- The Phylogeny of the Genus Clostridium: Proposal of Five New Genera and Eleven New Species CombinationsInternational Journal of Systematic and Evolutionary Microbiology, 1994